1. Home
  2. BGSF vs ACRV Comparison

BGSF vs ACRV Comparison

Compare BGSF & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BGSF Inc.

BGSF

BGSF Inc.

N/A

Current Price

$5.15

Market Cap

64.0M

ML Signal

N/A

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.99

Market Cap

74.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGSF
ACRV
Founded
2007
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.0M
74.0M
IPO Year
2013
2022

Fundamental Metrics

Financial Performance
Metric
BGSF
ACRV
Price
$5.15
$1.99
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$11.67
AVG Volume (30 Days)
6.2K
333.4K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
36.04%
N/A
EPS Growth
N/A
15.13
EPS
N/A
N/A
Revenue
$93,310,000.00
N/A
Revenue This Year
$4.67
N/A
Revenue Next Year
N/A
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.26
$1.27
52 Week High
$8.20
$3.56

Technical Indicators

Market Signals
Indicator
BGSF
ACRV
Relative Strength Index (RSI) 37.51 51.43
Support Level $4.99 $1.38
Resistance Level $5.79 $2.20
Average True Range (ATR) 0.15 0.12
MACD -0.02 -0.03
Stochastic Oscillator 5.71 18.57

Price Performance

Historical Comparison
BGSF
ACRV

About BGSF BGSF Inc.

BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. The company operates in one segment of Property Management, which includes centralized support services through executive, marketing, human resources, information technology, accounting, treasury, and billing operations.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: